What is HC Wainwright’s Forecast for DNTH FY2026 Earnings?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for Dianthus Therapeutics in a report issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($3.62) per share for the year, up from their prior estimate of ($3.87). HC Wainwright has a “Buy” rating and a $158.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2026 earnings at ($1.06) EPS, Q1 2027 earnings at ($1.12) EPS, Q2 2027 earnings at ($1.16) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.26) EPS, FY2027 earnings at ($4.76) EPS, FY2028 earnings at ($5.41) EPS, FY2029 earnings at ($5.42) EPS and FY2030 earnings at $2.35 EPS.

Several other brokerages have also issued reports on DNTH. Raymond James Financial reissued a “strong-buy” rating and issued a $134.00 price target on shares of Dianthus Therapeutics in a report on Thursday. Roth Capital initiated coverage on Dianthus Therapeutics in a research note on Tuesday, October 27th. They set a “buy” rating and a $113.00 price objective on the stock. Wedbush lifted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Citigroup began coverage on Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 target price on the stock. Finally, Truist Financial boosted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $128.77.

Dianthus Therapeutics Stock Performance

DNTH opened at $90.00 on Tuesday. The firm’s fifty day moving average is $89.73 and its two-hundred day moving average is $85.78. The firm has a market cap of $4.93 billion, a PE ratio of -22.56 and a beta of 1.47. Dianthus Therapeutics has a twelve month low of $34.29 and a twelve month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 21.15% and a negative net margin of 7,436.50%. The company had revenue of $1.21 million during the quarter, compared to analyst estimates of $0.46 million.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ABS Investment Management LLC acquired a new position in Dianthus Therapeutics during the second quarter valued at approximately $194,960,000. Fifth Third Bancorp grew its stake in shares of Dianthus Therapeutics by 23.6% in the third quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock valued at $60,000 after buying an additional 129 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after buying an additional 139 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Dianthus Therapeutics by 4.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,851 shares of the company’s stock worth $428,000 after buying an additional 209 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after buying an additional 254 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of Dianthus Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the transaction, the director owned 2,778 shares of the company’s stock, valued at approximately $326,553.90. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at $425,640. This trade represents a 85.25% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 45,902 shares of company stock worth $4,814,779. Company insiders own 3.02% of the company’s stock.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its estimates for 2026 and 2027, projecting smaller losses than before, and also reduced its estimated 2028 loss. The firm maintained a Buy rating and a $158 price target. MarketBeat analyst estimate report
• Positive Sentiment: A Zacks report said analysts’ average price target implied 61.23% potential upside and noted that upward earnings-estimate revisions can be a constructive signal. It cautioned, however, that price targets have limited predictive reliability. Zacks analyst price-target report
• Negative Sentiment: HC Wainwright sharply cut its longer-range forecasts: its 2029 estimate shifted from a small profit to a loss, and its 2030 profit estimate fell from $10.75 to $2.35 per share. Those revisions temper the more favorable near-term changes. MarketBeat analyst estimate report

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease.